Launches of Tuzulby® methylphenidate prolonged-release chewable tablets and Paxneury® guanfacine prolonged-release tablets, also in 5mg, 6mg, and 7mg strengthsTwo differentiated treatments exemplify ...
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that causes hyperactivity and impulsivity in children and adults. If left untreated ...
This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: ADHD and menopause symptoms can overlap, and one ...
Adults can have ADHD, often undiagnosed since childhood. Dr. Dania Antalaya explains symptoms, how adult diagnosis works, and ...
German CNS-focused specialist Neuraxpharm Group announced the launches in Europe of Tuzulby (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury (guanfacine) ...
9don MSN
Hyderabad-Based Pharmaceutical Gets US Nod For Generic ADHD Drug: Why This Matters And What It Means
ADHD is a neurodevelopmental condition that affects both children and adults. It is characterised by symptoms such as ...
9d
Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate ...
Do you suspect you or your loved ones have ADHD? Are you struggling with attention, focus, or hyperactivity? Are your symptoms starting to negatively impact your performance at school, work or even in ...
Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD
Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced that China's National Medical Products Administration ...
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback